ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, J.
Annals of Clinical and Laboratory Science, Vol 29, Issue 2, 106-111
Copyright © 1999 by Association of Clinical Scientists


Articles

Review of circulating tumor markers: from enzyme, carcinoembryonic protein to oncogene and suppressor gene

JT Wu

The ease and non-invasive nature of the procedure for drawing blood has made it possible to measure circulating tumor markers for cancer screening, diagnosis, follow-up and early detection of recurrence. Even though a tumor-specific marker has not yet been found, the specificity and sensitivity of currently used tumor markers have improved over the last several decades as they have progressed from enzyme, hormone and carcinoembryonic protein to monoclonal antibody-defined epitope and finally, in recent years, to oncogene, suppressor gene and their encoded protein product. Both phenotype and genotype are included in these latest new tumor markers. Unlike earlier tumor markers, they can be identified with specific biological processes regulating cell growth, such as the cell cycle, angiogenesis, apoptosis and cell adhesion. Any elevation of these new tumor markers, therefore, can be used to identify defects in a specific metabolic pathway and facilitate the design of effective drug therapy.


This article has been cited by other articles:


Home page
CarcinogenesisHome page
J. M. Cuezva, G. Chen, A. M. Alonso, A. Isidoro, D. E. Misek, S. M. Hanash, and D. G. Beer
The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis
Carcinogenesis, July 1, 2004; 25(7): 1157 - 1163.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Chen, T. G. Gharib, C.-C. Huang, D. G. Thomas, K. A. Shedden, J. M. G. Taylor, S. L. R. Kardia, D. E. Misek, T. J. Giordano, M. D. Iannettoni, et al.
Proteomic Analysis of Lung Adenocarcinoma: Identification of a Highly Expressed Set of Proteins in Tumors
Clin. Cancer Res., July 1, 2002; 8(7): 2298 - 2305.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. G. Rodrigues, A. Panizo-Santos, J. A. Cashel, H. C. Krutzsch, M. J. Merino, and D. D. Roberts
Semenogelins Are Ectopically Expressed in Small Cell Lung Carcinoma
Clin. Cancer Res., April 1, 2001; 7(4): 854 - 860.
[Abstract] [Full Text]


Home page
Genome ResHome page
W. T. Loging, A. Lal, I-M. Siu, T. L. Loney, C. J. Wikstrand, M. A. Marra, C. Prange, D. D. Bigner, R. L. Strausberg, and G. J. Riggins
Identifying Potential Tumor Markers and Antigens by Database Mining and Rapid Expression Screening
Genome Res., September 1, 2000; 10(9): 1393 - 1402.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Association of Clinical Scientists.